<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aurobindo Pharma Limited — News on 6ix</title>
<link>https://6ix.com/company/aurobindo-pharma-limited</link>
<description>Latest news and press releases for Aurobindo Pharma Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 22:34:34 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aurobindo-pharma-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836486778dffbe2df1521cb.webp</url>
<title>Aurobindo Pharma Limited</title>
<link>https://6ix.com/company/aurobindo-pharma-limited</link>
</image>
<item>
<title>Press Release Apr 17 2026</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-17-2026-3</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-17-2026-3</guid>
<pubDate>Fri, 17 Apr 2026 22:34:34 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 17, 2026, titled "Aurobindo Pharma receives USFDA approval for Dextromethorphan Polistirex Extended-Release Oral Suspension, 30 mg/5 mL (OTC)".</description>
</item>
<item>
<title>Press Release Apr 07 2026</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-07-2026-20</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-07-2026-20</guid>
<pubDate>Tue, 07 Apr 2026 22:18:28 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 07, 2026, titled "Aurobindo Pharma receives USFDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets".</description>
</item>
<item>
<title>Press Release Apr 06 2026</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-06-2026</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-06-2026</guid>
<pubDate>Mon, 06 Apr 2026 20:02:03 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 06, 2026, titled "Press Release - CuraTeQ Biologics Announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11".</description>
</item>
<item>
<title>Press Release Mar 04 2026</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-mar-04-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-mar-04-2026-1</guid>
<pubDate>Wed, 04 Mar 2026 17:13:52 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated March 04, 2026, titled "Eugia Pharma announces launch of Pomalidomide Capsules in the US".</description>
</item>
<item>
<title>Press Release Feb 26 2026</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-feb-26-2026-4</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-feb-26-2026-4</guid>
<pubDate>Thu, 26 Feb 2026 16:47:46 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated February 26, 2026, titled "Submission of press release that Eugia Pharma receives USFDA Approval for Everolimus Tablets.".</description>
</item>
<item>
<title>Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletolr-bempedoic-acid-and-nexlizetr-bempedoic-acid-and-ezetimibe-prior-to-april-19-2040</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletolr-bempedoic-acid-and-nexlizetr-bempedoic-acid-and-ezetimibe-prior-to-april-19-2040</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market</description>
</item>
<item>
<title>Press Release Feb 13 2026</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-feb-13-2026-6</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-feb-13-2026-6</guid>
<pubDate>Fri, 13 Feb 2026 23:34:40 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated February 13, 2026, titled "Press Release - Acrotech Biopharma Inc., Announces FDA Approval of ADQUEY (difamilast 1%) Ointment for the Treatment of Mild-to-Moderate Atopic Dermatitis".</description>
</item>
<item>
<title>Press Release Feb 09 2026</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-feb-09-2026-57</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-feb-09-2026-57</guid>
<pubDate>Tue, 10 Feb 2026 00:47:40 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated February 09, 2026, titled "Press Release on Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2025.".</description>
</item>
<item>
<title>Kargo.ai Raises $42M Series B to Scale Global Warehouse Deployment with Enterprise Clients</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/kargoai-raises-dollar42m-series-b-to-scale-global-warehouse-deployment-with-enterprise-clients</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/kargoai-raises-dollar42m-series-b-to-scale-global-warehouse-deployment-with-enterprise-clients</guid>
<pubDate>Mon, 22 Dec 2025 14:01:00 GMT</pubDate>
<description>SAN FRANCISCO, December 22, 2025--Kargo, a leader in industrial artificial intelligence (AI) technology for supply chain and logistics, today announced the closing of a $42 million Series B funding round. The round was led by Avenir, with participation from Linse Capital, Hearst Ventures and Lightbank, and previous investors Matter Venture Partners and Sozo Ventures. The new capital will be used to accelerate Kargo’s mission to transform real-time inventory data infrastructure across warehousing</description>
</item>
<item>
<title>Press Release Nov 05 2025</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-nov-05-2025-3</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-nov-05-2025-3</guid>
<pubDate>Thu, 06 Nov 2025 01:02:31 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Press Release".</description>
</item>
<item>
<title>Press Release Aug 04 2025</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-aug-04-2025-5</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-aug-04-2025-5</guid>
<pubDate>Mon, 04 Aug 2025 23:46:53 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated August 04, 2025, titled "Press Release".</description>
</item>
<item>
<title>Press Release May 26 2025</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-may-26-2025</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-may-26-2025</guid>
<pubDate>Mon, 26 May 2025 23:44:43 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated May 26, 2025, titled "Press Release on Audited Financial Results for the quarter and year ended March 31, 2025".</description>
</item>
<item>
<title>Press Release May 13 2025</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-may-13-2025-6</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-may-13-2025-6</guid>
<pubDate>Tue, 13 May 2025 22:00:43 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated May 13, 2025, titled "CuraTeQ Biologics receives approval for biosimilar Zefylti from UK s MHRA".</description>
</item>
<item>
<title>Press Release Apr 26 2025</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-26-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-26-2025-1</guid>
<pubDate>Sat, 26 Apr 2025 13:36:23 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 26, 2025, titled "CuraTeQ Biologics s.r.o, a wholly owned step-down subsidiary of the Company, receives Positive Opinion from CHMP for Dazublys?, a Trastuzumab Biosimilar".</description>
</item>
<item>
<title>Press Release Apr 23 2025</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-23-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-23-2025-2</guid>
<pubDate>Wed, 23 Apr 2025 15:23:59 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 23, 2025, titled "Eugia Pharma receives USFDA approval for Dasatinib Tablets".</description>
</item>
<item>
<title>Press Release Apr 12 2025</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-12-2025</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-12-2025</guid>
<pubDate>Sun, 13 Apr 2025 01:20:56 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 12, 2025, titled "Aurobindo Pharma receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg and tentative approval for other strengths of Rivaroxaban Tablets USP".</description>
</item>
<item>
<title>Press Release Apr 09 2025</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-09-2025</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-apr-09-2025</guid>
<pubDate>Wed, 09 Apr 2025 21:24:22 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 09, 2025, titled "CuraTeQ Biologics completes a successful Phase 1 Pharmacokinetics study of Denosumab BP16, a proposed biosimilar to Prolia? and Xgeva?".</description>
</item>
<item>
<title>Press Release Feb 06 2025</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-feb-06-2025-7</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-feb-06-2025-7</guid>
<pubDate>Fri, 07 Feb 2025 01:12:40 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated February 06, 2025, titled "Press Release on Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2024".</description>
</item>
<item>
<title>Press Release Jan 31 2025</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-jan-31-2025-4</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-jan-31-2025-4</guid>
<pubDate>Fri, 31 Jan 2025 23:43:43 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated January 31, 2025, titled "CuraTeQ Biologics s.r.o, receives positive opinion from CHMP / EMA for Dyrupeg".</description>
</item>
<item>
<title>Press Release Dec 21 2024</title>
<link>https://6ix.com/company/aurobindo-pharma-limited/news/press-release-dec-21-2024</link>
<guid isPermaLink="true">https://6ix.com/company/aurobindo-pharma-limited/news/press-release-dec-21-2024</guid>
<pubDate>Sat, 21 Dec 2024 17:15:33 GMT</pubDate>
<description>Aurobindo Pharma Limited has informed the Exchange regarding a press release dated December 21, 2024, titled "CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK s MHRA".</description>
</item>
</channel>
</rss>